AstraZeneca Plc (AZN) said an experimental cancer drug shrank tumors in half of patients in an early-stage study, a result that may help its case that Pfizer Inc. (NYSE:PFE)’s takeover bid substantially undervalues the company. Pfizer Inc. (NYSE:PFE) net profit margin is 81.20% and weekly performance is 0.28%. On last trading day company shares ended up $29.10. Analysts mean target price for the company is $33.97. Pfizer Inc. (NYSE:PFE) distance from 50-day simple moving average (SMA50) is -5.92%.
When the world’s leading cancer doctors meet in Chicago next month, new treatments from Merck & Co., Inc. (NYSE:MRK), Bristol-Myers Squibb Co and Roche Holding AG that help the immune system fight disease are expected to capture much of the spotlight. Merck & Co., Inc. (NYSE:MRK) shares advanced 1.11% in last trading session and ended the day on $56.37. MRK Gross Margin is 61.30% and its return on assets is 5.70%. Merck & Co., Inc. (NYSE:MRK) quarterly performance is 3.30%.
Bristol-Myers Squibb Co (NYSE:BMY) announced results from a Phase1b study evaluating the safety and efficacy of its investigational PD-1 immune checkpoint inhibitor nivolumab as a single agent in patients with advanced non-small cell lung cancer, NSCLC, who were previously treated and a Phase 1b study evaluating nivolumab as a single agent in chemotherapy-naïve patients. In Study -003, the two-year survival rate was 24% across doses for previously-treated patients who received nivolumab as a single agent and highest at 45% in patients who received the 3 mg/kg dose. In CheckMate -012, the overall response rate was 50% in PD-L1 positive tumors and 0% in PD-L1 negative tumors for chemotherapy-naïve patients who received nivolumab as a single agent. Bristol-Myers Squibb Co (NYSE:BMY) shares moved down -0.13% in last trading session and was closed at $52.12, while trading in range of $51.75 – $52.39. Bristol-Myers Squibb Co (NYSE:BMY) year to date (YTD) performance is -1.25%.
GlaxoSmithKline plc (ADR) (NYSE:GSK) former China chief Mark Reilly was accused by Chinese authorities of ordering his subordinates and other employees to bribe hospital doctors, health-care organizations and other parties on “a large scale” to boost Glaxo’s drug sales in China, the Wall Street Journal reports. GlaxoSmithKline plc (ADR) (NYSE:GSK) ended the last trading day at $55.19. Company weekly volatility is calculated as 1.02% and price to cash ratio as 22.11. GlaxoSmithKline plc (ADR) (NYSE:GSK) showed a positive weekly performance of 0.69%.